Omeros (NASDAQ:OMER) Raised to Hold at StockNews.com

Omeros (NASDAQ:OMER) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

Other analysts also recently issued reports about the company. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Tuesday. D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Price Performance

OMER opened at $8.01 on Tuesday. Omeros has a fifty-two week low of $2.97 and a fifty-two week high of $13.60. The company’s 50 day moving average price is $8.61 and its two-hundred day moving average price is $7.61. The firm has a market capitalization of $464.18 million, a price-to-earnings ratio of -3.47 and a beta of 2.03.

Institutional Trading of Omeros

A number of large investors have recently bought and sold shares of OMER. Charles Schwab Investment Management Inc. lifted its stake in shares of Omeros by 4.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after purchasing an additional 18,454 shares during the period. BNP Paribas Financial Markets increased its holdings in Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares in the last quarter. HighTower Advisors LLC lifted its stake in Omeros by 7.2% in the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 4,000 shares during the period. State Street Corp boosted its holdings in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after buying an additional 3,839 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Omeros during the 3rd quarter worth approximately $305,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.